Onco-Innovations Limited
W1H.F
0.33 EUR
1 day: N/A
The alert is saved directly without jumping back to the homepage.
Price alerts for W1H.F
Please log in to view and save price alerts.
Finanzen
Company info
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.
Aktuelle News
-
Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Vorschau anzeigen
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its analytical reference standard preparation program ...
-
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Vorschau anzeigen
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Company") is pleased to announce that it has executed ...
-
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Vorschau anzeigen
VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated June 23, 2026, the initiation of ...
-
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Vorschau anzeigen
VANCOUVER, BC / ACCESS Newswire / June 26, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010, ...
-
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Vorschau anzeigen
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "Company") announced the successful completion of ...